tiprankstipranks
Aspire Biopharma Holdings (ASBP)
NASDAQ:ASBP
US Market

Aspire Biopharma Holdings (ASBP) Ownership - Who Owns Aspire Biopharma Holdings?

196 Followers

Aspire Biopharma Holdings (ASBP) Ownership Overview

1.54%0.79%0.61%97.06%
0.61% ETFs
97.06% Public Companies and
Individual Investors
The ownership structure of Aspire Biopharma Holdings (ASBP) stock is a mix of institutional, retail, and individual investors. , 1.54% is owned by Insiders, and 97.06% is owned by Public Companies and Individual Investors.
The ownership structure of Aspire Biopharma Holdings (ASBP) stock is a mix of institutional, retail, and individual investors. Approximately 1.39% of the company’s stock is owned by Institutional Investors, 1.54% is owned by Insiders, and 97.06% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Jun 06, 2025
xxxxxxxxxxxxx
$7800

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
20,000Insider1.54%109,800
10,207Institution0.79%56,036
10,000Institution0.77%54,900
7,859Institution0.61%43,146

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
10,207Institution0.79%56,036

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
7,859Institution0.61%8,095

FAQ

Who Owns Aspire Biopharma Holdings (ASBP)?
Currently, no data Available
What percentage of Aspire Biopharma Holdings (ASBP) stock is held by institutional investors?
Currently, no data Available
What percentage of Aspire Biopharma Holdings (ASBP) stock is held by retail investors?
According to the latest TipRanks data, approximately 97.06% of Aspire Biopharma Holdings (ASBP) stock is held by retail investors.
    Who owns the most shares of Aspire Biopharma Holdings (ASBP)?
    Donald G. Fell owns the most shares of Aspire Biopharma Holdings (ASBP).
      What is the significance of the ownership structure for a publicly traded company?
      The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.